9.39

0.00% 0.00

After Hours: 9.68 0.29 +3.09%

Prothena Corp Plc (PRTA)

Overview News Price History Option Chain Financials Why PRTA Down? Discussions Forecast

Prothena Corp Plc stock is traded at $9.39, with a volume of 248.12K. It is up +0.00% in the last 24 hours and up +7.31% over the past month. Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Previous Close:

$9.39

Open:

$9.46

24h Volume:

248.12K

Relative Volume:

0.46

Market Cap:

$482.05M

Revenue:

$57.94M

Net Income/Loss:

$-151.18M

P/E Ratio:

-3.3397

EPS:

-2.8116

Net Cash Flow:

$-86.56M

1W Performance:

+5.74%

1M Performance:

+7.31%

6M Performance:

+4.68%

1Y Performance:

+7.07%

1-Day Range:

$9.19

$9.49

1-Week Range:

$8.58

$9.52

52-Week Range:

$7.73

$11.80

Prothena Corp Plc Stock (PRTA) Company Profile

Name

Prothena Corp Plc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

011-353-1-236-2500

Address

77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2

Employee

Twitter

@ProthenaCorp

Next Earnings Date

2026-08-03

Latest SEC Filings

PRTA's Discussions on Twitter

Compare PRTA vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRTA Prothena Corp Plc	9.39	463.57M	57.94M	-151.18M	-86.56M	-2.8116
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-27-25	Downgrade	Jefferies	Buy → Hold
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Apr-24-23	Initiated	SVB Securities	Outperform
Jan-27-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral
Jun-08-21	Reiterated	Oppenheimer	Outperform
May-26-21	Initiated	Citigroup	Buy
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-12-21	Upgrade	Jefferies	Hold → Buy
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy
Dec-07-20	Initiated	H.C. Wainwright	Buy
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform
Nov-19-19	Upgrade	Evercore ISI	In-line → Outperform
May-21-18	Downgrade	Barclays	Equal Weight → Underweight
Apr-23-18	Downgrade	Jefferies	Buy → Hold
Apr-05-18	Reiterated	Barclays	Overweight
Nov-20-17	Downgrade	Wedbush	Outperform → Neutral
Sep-29-17	Reiterated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-11-17	Initiated	Jefferies	Buy
Apr-12-17	Initiated	Cantor Fitzgerald	Overweight
Apr-12-17	Initiated	Piper Jaffray	Overweight
Mar-02-17	Initiated	Instinet	Buy
Dec-21-16	Initiated	SunTrust	Buy
Nov-03-16	Initiated	Deutsche Bank	Buy
Aug-04-16	Reiterated	Barclays	Overweight
May-13-16	Initiated	Barclays	Overweight
Feb-19-16	Reiterated	Wedbush	Outperform
Jan-21-16	Initiated	Credit Suisse	Outperform

View All

Prothena Corp Plc Stock (PRTA) Latest News

Aug 21, 2026

Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock - MarketBeat

Aug 21, 2026

Aug 19, 2026

Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Aug 19, 2026

Aug 12, 2026

Precision Trading with Prothena Corporation Plc (PRTA) Risk Zones - Stock Traders Daily

Aug 12, 2026

Aug 11, 2026

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - tradingview.com

Aug 07, 2026

Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

Aug 07, 2026

Aug 06, 2026

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Aug 06, 2026

Prothena Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com

Aug 06, 2026

Prothena: Q2 Earnings Snapshot - marketscreener.com

Aug 06, 2026

Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone - Stock Titan

Aug 06, 2026

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - marketscreener.com

Aug 06, 2026

FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4% - stocktitan.net

Aug 06, 2026

Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA - MarketBeat

Aug 06, 2026

Aug 04, 2026

Prothena Corporation PLC expected to post a loss of 39 cents a shareEarnings Preview - tradingview.com

Aug 04, 2026

Aug 01, 2026

Technical Reactions to PRTA Trends in Macro Strategies - Stock Traders Daily

Aug 01, 2026

Jul 31, 2026

Prothena (NASDAQ:PRTA) Insider Anne Evans Kingston Sells 7,662 Shares of Stock - MarketBeat

Jul 31, 2026

Jul 30, 2026